Articles By Jack Cush, MD
Clinical Trial Boom or Bust in Severe COVID-19
By Jack Cush, MD
20 October 2020
A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection. Remdesivir
Read Article
Biologic Use for Arthritis Linked With Depression and Anxiety
By Jack Cush, MD
20 October 2020
In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian University of Athens, and colleagues in RMD Open: Rheumatic & Musculoskeletal Diseases.
Read Article
Outpatient Visits Return to Pre-COVID Rates
By Jack Cush, MD
19 October 2020
The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.
Read Article
TNF Inhibitors or non-TNF Biologics - First Best Choice?
By Jack Cush, MD
18 October 2020
Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar
Read Article
RheumNow Podcast – Good Time Charlie…. (10.16.20)
By Jack Cush, MD
15 October 2020
Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.
Read Article
Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis
By Jack Cush, MD
15 October 2020
NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.
Read Article
COVID Transmission from Young to Old
By Jack Cush, MD
13 October 2020
The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.
Read Article
Tofacitinib and Thromboembolic Risk
By Jack Cush, MD
13 October 2020
Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m
Read Article
Thrombotic Risk in Rheumatoid Arthritis Linked to Disease Activity
By Jack Cush, MD
11 October 2020
A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.
Read Article
Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients
By Jack Cush, MD
09 October 2020
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
Read Article